NextCure Competitors
| NXTC Stock | USD 10.85 0.43 4.13% |
NextCure vs Iterum Therapeutics Correlation
Very good diversification
The correlation between NextCure and ITRM is -0.49 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and ITRM in the same portfolio, assuming nothing else is changed.
Moving against NextCure Stock
| 0.63 | ACLX | Arcellx | PairCorr |
| 0.56 | RANI | Rani Therapeutics | PairCorr |
| 0.47 | APLT | Applied Therapeutics | PairCorr |
| 0.44 | EVGN | Evogene | PairCorr |
| 0.39 | LYRA | Lyra Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NextCure's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NextCure Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between NextCure and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of NextCure and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of NextCure does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between NextCure Stock performing well and NextCure Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze NextCure's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| QTTB | 4.86 | 0.90 | 0.15 | (1.51) | 4.85 | 7.51 | 85.16 | |||
| PSTV | 4.84 | (1.26) | 0.00 | (0.48) | 0.00 | 8.93 | 48.30 | |||
| BOLD | 2.07 | (0.36) | 0.00 | (0.81) | 0.00 | 4.13 | 16.75 | |||
| VRCA | 5.41 | 1.17 | 0.22 | 0.52 | 4.72 | 13.76 | 52.65 | |||
| ANTX | 2.61 | (0.22) | 0.00 | (0.33) | 0.00 | 4.55 | 32.31 | |||
| JSPR | 4.22 | (0.46) | 0.00 | 0.53 | 0.00 | 7.73 | 31.75 | |||
| INTS | 13.68 | 4.63 | 0.41 | (31.00) | 8.40 | 12.20 | 433.59 | |||
| PLUR | 3.77 | (0.10) | 0.00 | (0.03) | 0.00 | 9.30 | 31.25 | |||
| TAOX | 5.83 | (0.73) | 0.00 | (0.43) | 0.00 | 12.66 | 36.28 | |||
| ITRM | 4.41 | (1.08) | 0.00 | (0.49) | 0.00 | 9.38 | 28.58 |
Cross Equities Net Income Analysis
Compare NextCure and related stocks such as Q32 Bio, Plus Therapeutics, and Boundless Bio Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTTB | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (30 M) | (55.6 M) | (103.9 M) | (128.7 M) | (95.8 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
| PSTV | (2.1 M) | (32.5 M) | (32.3 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (10.9 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (11.7 M) | (12.3 M) |
| BOLD | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (90.2 M) | (128.8 M) | (25.2 M) | (25.2 M) | (25.2 M) | (45.9 M) | (49.4 M) | (65.4 M) | (75.2 M) | (78.9 M) |
| VRCA | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (4.5 M) | (20.6 M) | (27.9 M) | (45.5 M) | (35.1 M) | (24.5 M) | (67 M) | (76.6 M) | (68.9 M) | (65.5 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| JSPR | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (31.7 M) | (30.6 M) | (37.7 M) | (64.5 M) | (71.3 M) | (64.1 M) | (67.3 M) |
| INTS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| PLUR | (77.9 K) | (14.8 M) | (21.2 M) | (26.9 M) | (24.7 M) | (23.2 M) | (27.8 M) | (26.1 M) | (35.3 M) | (29.2 M) | (49.9 M) | (41.2 M) | (28.3 M) | (20.9 M) | (22.6 M) | (20.3 M) | (21.3 M) |
| TAOX | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (5.6 M) | (6 M) | (12.8 M) | (11.5 M) | (12.1 M) |
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
NextCure and related stocks such as Q32 Bio, Plus Therapeutics, and Boundless Bio Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in NextCure financial statement analysis. It represents the amount of money remaining after all of NextCure operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.NextCure Competitive Analysis
The better you understand NextCure competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, NextCure's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across NextCure's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
NextCure Competition Performance Charts
Five steps to successful analysis of NextCure Competition
NextCure's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by NextCure in relation to its competition. NextCure's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of NextCure in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact NextCure's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to NextCure, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your NextCure position
In addition to having NextCure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Financials Thematic Idea Now
Financials
Companies that provide financial services to business or retail customers. The Financials theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Financials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out NextCure Correlation with its peers. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Will Biotechnology sector continue expanding? Could NextCure diversify its offerings? Factors like these will boost the valuation of NextCure. Anticipated expansion of NextCure directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NextCure data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between NextCure's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NextCure should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, NextCure's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.